WA
GILD icon

WESPAC Advisors’s Gilead Sciences GILD Stock Holding History

WESPAC Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Sell
2,272
-4,997
-69% -$658K 0.14% 153
2026
Q1 		$1.01M Buy
7,269
+940
+15% +$132K 0.55% 53
2025
Q4 		$777K Buy
+6,329
New +$769K 0.42% 75
2025
Q3 		– Sell
-9,495
Closed -$1.05M – 192
2025
Q2 		$1.05M Buy
9,495
+7,248
+323% +$771K 0.74% 42
2025
Q1 		$252K Buy
+2,247
New +$232K 0.21% 136
2024
Q2 		– Sell
-2,885
Closed -$211K – 161
2024
Q1 		$211K Sell
2,885
-44
-2% -$3.38K 0.12% 157
2023
Q4 		$237K Buy
2,929
+1
+0% +$78 0.16% 133
2023
Q3 		$219K Buy
+2,928
New +$225K 0.16% 130
2016
Q2 		– Sell
-15,112
Closed -$1.39M – 111
2016
Q1 		$1.39M Buy
+15,112
New +$1.36M 1.73% 15
2014
Q2 		– Sell
-14,190
Closed -$1.01M – 119
2014
Q1 		$1.01M Buy
14,190
+1,692
+14% +$133K 0.87% 37
2013
Q4 		$939K Buy
12,498
+6,191
+98% +$431K 0.78% 50
2013
Q3 		$397K Buy
+6,307
New +$377K 0.46% 80

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WESPAC Advisors's GILD Position: Q2 2026 in Review

WESPAC Advisors reduced its Gilead Sciences (GILD) stake by 69% in Q2 2026, selling an estimated $658K and leaving 2,272 shares worth $287K. The position accounts for 0.14% of the portfolio, ranked #153.

WESPAC Advisors first reported a position in GILD in Q3 2013 and has held it in 12 quarters since. The position peaked at $1.39M in Q1 2016. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • WESPAC Advisors held 2,272 shares of Gilead Sciences worth $287K as of Q2 2026.
  • WESPAC Advisors sold 4,997 Gilead Sciences shares in Q2 2026, an estimated $658K.
  • Gilead Sciences made up 0.14% of WESPAC Advisors's portfolio in Q2 2026, its #153 holding.
  • WESPAC Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 12 quarters since.
  • WESPAC Advisors's Gilead Sciences position peaked at $1.39M in Q1 2016.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on WESPAC Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.